Addex Therapeutics Ltd ADXN
NASDAQ
| 03/31/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -82.35% | -40.19% | -- |
| Total Other Revenue | -87.59% | -87.59% | -- | 376.92% | 4,837.50% |
| Total Revenue | -87.59% | -87.59% | 1,064.71% | -8.15% | -70.60% |
| Cost of Revenue | -73.44% | -73.44% | -11.16% | 20.73% | -38.09% |
| Gross Profit | 61.63% | 61.63% | 36.31% | -32.19% | -708.55% |
| SG&A Expenses | -0.67% | -0.67% | 113.73% | 17.53% | -34.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.44% | -17.44% | 95.44% | 18.49% | -35.61% |
| Operating Income | 9.22% | 9.22% | -92.23% | -20.98% | 25.18% |
| Income Before Tax | -33.29% | -33.29% | -69.39% | -11.64% | -94.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.29% | -33.29% | -69.39% | -11.64% | -94.86% |
| Earnings from Discontinued Operations | -- | -- | 76.24% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.29% | -33.29% | -67.47% | -11.46% | 53.60% |
| EBIT | 9.22% | 9.22% | -92.23% | -20.98% | 25.18% |
| EBITDA | 8.93% | 8.93% | -103.06% | -32.35% | 25.17% |
| EPS Basic | -10.18% | -10.18% | -39.29% | 2.78% | 53.87% |
| Normalized Basic EPS | -10.58% | -10.58% | -41.86% | 2.68% | -92.59% |
| EPS Diluted | -10.18% | -10.18% | -39.29% | 2.78% | 53.87% |
| Normalized Diluted EPS | -10.58% | -10.58% | -41.86% | 2.68% | -92.59% |
| Average Basic Shares Outstanding | 20.52% | 20.52% | 19.88% | 14.62% | 0.83% |
| Average Diluted Shares Outstanding | 20.52% | 20.52% | 19.88% | 14.62% | 0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |